Synairgen reports 'significant progress'

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June.

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June.

The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the potential of SNG001 as a broad spectrum antiviral.

In October Synairgen submitted a competitive contract tender to the US National Institute of Allergy and Infectious Diseases, which, if successful, would result in a contract being awarded in the second half of 2013.

Meanwhile, analysis of gene and protein biomarkers in samples from the Phase II study in asthma have been initiated, and advancements have been made in its clinical development plan for both the asthma and Chronic Obstructive Pulmonary Disease (COPD).

The company has also expanded its patent portfolio through the grant of a US patent for compounds that induce interferon beta to treat or prevent rhinovirus infections.

Richard Marsden, Chief Executive, said: "This has been an extremely busy period for the company. We have significantly progressed discussions with various potential licensing partners for SNG001 in asthma and COPD and commenced biomarker and further analysis of the samples from the Phase II asthma study.

"In addition, the patent portfolio has been substantially enhanced. We are excited by the potential of our lead programmes and looking forward to progressing their development in 2013."

The share price rose 3.23% to 48p by 11:35.

NR

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022